xRapid
xRapid is a technology company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
xRapid is a technology company.
xRapid Group is a France-based health tech startup founded in 2015 that develops AI-powered mobile diagnostic tools to enable rapid, reliable testing for diseases and health conditions at home or in the field.[1][2][3] It serves healthcare providers, patients, and global health initiatives by solving the problem of accessible, accurate point-of-care diagnostics, particularly in remote or resource-limited settings, with products like malaria detection (2015), fiber analysis (2018), at-home blood tests (CES 2020 award winner), xRcovid for COVID-19 rapid test analysis, and xRfiber for automated air testing.[1][3] The company operates internationally across France, Great Britain, the US, and China with 20-50 employees, showing steady growth through prototype/MVP stages and innovation awards.[1]
xRapid Group was founded in 2015 in Aix-en-Provence, France, by Jean Viry-Babel, who serves as CEO, alongside advisor Oksana Simakov and a team of health, blood biochemistry, AI, and image analysis experts.[1][3] The idea emerged from a mission to improve lives via AI-driven diagnostics, starting with a malaria detection app that same year, followed by expansions into fiber analysis and blood testing innovations.[1] Early traction included winning a CES 2020 innovation award in health and wellness for at-home blood tests, and launching the xRcovid app during the pandemic for AI-verified COVID-19 rapid tests, marking pivotal moments in global health crises.[1]
xRapid Group's strengths lie in its AI-centric approach to mobile health diagnostics, setting it apart in the medtech space:
xRapid rides the AI-in-healthcare wave, accelerating post-COVID demand for decentralized diagnostics amid trends like telehealth expansion and global health equity.[1][2] Timing aligns with rising needs for rapid, scalable testing in pandemics and chronic disease monitoring, fueled by market forces such as smartphone proliferation and AI advancements in image recognition.[3] It influences the ecosystem by pioneering mobile AI tools that reduce lab dependency, supporting biotech pilots and crowdfunding like its MedStartr xRcovid campaign, potentially lowering barriers for emerging markets.[1]
xRapid is poised to expand its AI diagnostic portfolio into new areas like environmental health (e.g., xRfiber scaling) and chronic disease tracking, leveraging post-pandemic momentum and global partnerships.[1][3] Trends like edge AI on mobiles and regulatory nods for at-home tests will propel growth, evolving its role from niche innovator to key player in accessible medtech. As AI diagnostics mature, xRapid's focus on reliability could redefine point-of-care testing worldwide, building on its CES-validated foundation.[1]